Literature DB >> 14617757

In vivo selection of MGMT(P140K) lentivirus-transduced human NOD/SCID repopulating cells without pretransplant irradiation conditioning.

Steven P Zielske1, Jane S Reese, Karen T Lingas, Jon R Donze, Stanton L Gerson.   

Abstract

Infusion of transduced hematopoietic stem cells into nonmyeloablated hosts results in ineffective in vivo levels of transduced cells. To increase the proportion of transduced cells in vivo, selection based on P140K O6-methylguanine-DNA-methyltransferase (MGMT[P140K]) gene transduction and O6-benzylguanine/1,3-bis(2-chloroethyl)-1-nitrosourea (BG/BCNU) treatment has been devised. In this study, we transduced human NOD/SCID repopulating cells (SRCs) with MGMT(P140K) using a lentiviral vector and infused them into BG/BCNU-conditioned NOD/SCID mice before rounds of BG/BCNU treatment as a model for in vivo selection. Engraftment was not observed until the second round of BG/BCNU treatment, at which time human cells emerged to compose up to 20% of the bone marrow. Furthermore, 99% of human CFCs derived from NOD/SCID mice were positive for provirus as measured by PCR, compared with 35% before transplant and 11% in untreated irradiation-preconditioned mice, demonstrating selection. Bone marrow showed BG-resistant O6-alkylguanine-DNA-alkyltransferase (AGT) activity, and CFUs were stained intensely for AGT protein, indicating high transgene expression. Real-time PCR estimates of the number of proviral insertions in individual CFUs ranged from 3 to 22. Selection resulted in expansion of one or more SRC clones containing similar numbers of proviral copies per mouse. To our knowledge, these results provide the first evidence of potent in vivo selection of MGMT(P140K) lentivirus-transduced human SRCs following BG/BCNU treatment.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14617757      PMCID: PMC259124          DOI: 10.1172/JCI17922

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  36 in total

1.  Limiting numbers of G156A O(6)-methylguanine-DNA methyltransferase-transduced marrow progenitors repopulate nonmyeloablated mice after drug selection.

Authors:  B M Davis; O N Koç; S L Gerson
Journal:  Blood       Date:  2000-05-15       Impact factor: 22.113

2.  Many multipotential gene-marked progenitor or stem cell clones contribute to hematopoiesis in nonhuman primates.

Authors:  H J Kim; J F Tisdale; T Wu; M Takatoku; S E Sellers; P Zickler; M E Metzger; B A Agricola; J D Malley; I Kato; R E Donahue; K E Brown; C E Dunbar
Journal:  Blood       Date:  2000-07-01       Impact factor: 22.113

3.  Detection and direct genomic sequencing of multiple rare unknown flanking DNA in highly complex samples.

Authors:  M Schmidt; G Hoffmann; M Wissler; N Lemke; A Müssig; H Glimm; D A Williams; S Ragg; C U Hesemann; C von Kalle
Journal:  Hum Gene Ther       Date:  2001-05-01       Impact factor: 5.695

4.  Efficient retrovirus-mediated transfer of the multidrug resistance 1 gene into autologous human long-term repopulating hematopoietic stem cells.

Authors:  R Abonour; D A Williams; L Einhorn; K M Hall; J Chen; J Coffman; C M Traycoff; A Bank; I Kato; M Ward; S D Williams; R Hromas; M J Robertson; F O Smith; D Woo; B Mills; E F Srour; K Cornetta
Journal:  Nat Med       Date:  2000-06       Impact factor: 53.440

5.  Transduction of human CD34+ CD38- bone marrow and cord blood-derived SCID-repopulating cells with third-generation lentiviral vectors.

Authors:  G Guenechea; O I Gan; T Inamitsu; C Dorrell; D S Pereira; M Kelly; L Naldini; J E Dick
Journal:  Mol Ther       Date:  2000-06       Impact factor: 11.454

6.  Cytogenetics of the chronic myeloid leukemia-derived cell line K562: karyotype clarification by multicolor fluorescence in situ hybridization, comparative genomic hybridization, and locus-specific fluorescence in situ hybridization.

Authors:  S M Gribble; I Roberts; C Grace; K M Andrews; A R Green; E P Nacheva
Journal:  Cancer Genet Cytogenet       Date:  2000-04-01

7.  Protection and in vivo selection of hematopoietic stem cells using temozolomide, O6-benzylguanine, and an alkyltransferase-expressing retroviral vector.

Authors:  N Sawai; S Zhou; E F Vanin; P Houghton; T P Brent; B P Sorrentino
Journal:  Mol Ther       Date:  2001-01       Impact factor: 11.454

8.  Direct reversal of DNA damage by mutant methyltransferase protein protects mice against dose-intensified chemotherapy and leads to in vivo selection of hematopoietic stem cells.

Authors:  S Ragg; M Xu-Welliver; J Bailey; M D'Souza; R Cooper; S Chandra; R Seshadri; A E Pegg; D A Williams
Journal:  Cancer Res       Date:  2000-09-15       Impact factor: 12.701

9.  Lentiviral vectors for enhanced gene expression in human hematopoietic cells.

Authors:  A Ramezani; T S Hawley; R G Hawley
Journal:  Mol Ther       Date:  2000-11       Impact factor: 11.454

10.  Gene transfer by lentiviral vectors is limited by nuclear translocation and rescued by HIV-1 pol sequences.

Authors:  A Follenzi; L E Ailles; S Bakovic; M Geuna; L Naldini
Journal:  Nat Genet       Date:  2000-06       Impact factor: 38.330

View more
  34 in total

1.  High-level beta-globin expression and preferred intragenic integration after lentiviral transduction of human cord blood stem cells.

Authors:  Suzan Imren; Mary E Fabry; Karen A Westerman; Robert Pawliuk; Patrick Tang; Patricia M Rosten; Ronald L Nagel; Philippe Leboulch; Connie J Eaves; R Keith Humphries
Journal:  J Clin Invest       Date:  2004-10       Impact factor: 14.808

2.  Treatment of a solid tumor using engineered drug-resistant immunocompetent cells and cytotoxic chemotherapy.

Authors:  Anindya Dasgupta; Jordan E Shields; H Trent Spencer
Journal:  Hum Gene Ther       Date:  2012-04-18       Impact factor: 5.695

Review 3.  Towards in vivo amplification: Overcoming hurdles in the use of hematopoietic stem cells in transplantation and gene therapy.

Authors:  Murtaza S Nagree; Lucía López-Vásquez; Jeffrey A Medin
Journal:  World J Stem Cells       Date:  2015-12-26       Impact factor: 5.326

Review 4.  Survival of the fittest: in vivo selection and stem cell gene therapy.

Authors:  Tobias Neff; Brian C Beard; Hans-Peter Kiem
Journal:  Blood       Date:  2005-11-03       Impact factor: 22.113

5.  PDGFB-based stem cell gene therapy increases bone strength in the mouse.

Authors:  Wanqiu Chen; David J Baylink; Justin Brier-Jones; Amanda Neises; Jason B Kiroyan; Charles H Rundle; Kin-Hing William Lau; Xiao-Bing Zhang
Journal:  Proc Natl Acad Sci U S A       Date:  2015-07-06       Impact factor: 11.205

Review 6.  Recent advances in lentiviral vector development and applications.

Authors:  Janka Mátrai; Marinee K L Chuah; Thierry VandenDriessche
Journal:  Mol Ther       Date:  2010-01-19       Impact factor: 11.454

7.  Efficiency and safety of O⁶-methylguanine DNA methyltransferase (MGMT(P140K))-mediated in vivo selection in a humanized mouse model.

Authors:  Ruhi Phaltane; Reinhard Haemmerle; Michael Rothe; Ute Modlich; Thomas Moritz
Journal:  Hum Gene Ther       Date:  2014-01-07       Impact factor: 5.695

8.  Engineered drug-resistant immunocompetent cells enhance tumor cell killing during a chemotherapy challenge.

Authors:  Anindya Dasgupta; David McCarty; H Trent Spencer
Journal:  Biochem Biophys Res Commun       Date:  2009-11-10       Impact factor: 3.575

9.  Suppression of HLA expression by lentivirus-mediated gene transfer of siRNA cassettes and in vivo chemoselection to enhance hematopoietic stem cell transplantation.

Authors:  Katrin Hacke; Rustom Falahati; Linda Flebbe-Rehwaldt; Noriyuki Kasahara; Karin M L Gaensler
Journal:  Immunol Res       Date:  2009       Impact factor: 2.829

10.  Stable differentiation and clonality of murine long-term hematopoiesis after extended reduced-intensity selection for MGMT P140K transgene expression.

Authors:  Claudia R Ball; Ingo H Pilz; Manfred Schmidt; Sylvia Fessler; David A Williams; Christof von Kalle; Hanno Glimm
Journal:  Blood       Date:  2007-05-11       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.